Osimertinib

Spezifikationen

1421373-65-0CAS-Nummer

108-168-8EG-Nummer

N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamideIUPAC-Name

C28H33N7O2Chemische Formel

499.6 g/molMolekulargewicht

osimertinib; 1421373-65-0; AZD-9291; Mereletinib; AZD9291; AZD 9291; osimertinibum; N-(2-{[2-(Dimethylamino)ethyl](Methyl)amino}-4-Methoxy-5-{[4-(1-Methyl-1h-Indol-3-Yl)pyrimidin-2-Yl]amino}phenyl)prop-2-Enamide; 3C06JJ0Z2O; AZD-9291 FREE BASE; N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide; N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide; CHEBI:90943; DTXSID501025961; 2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-; 2-Propenamide, N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-; N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)prop-2-enamide; N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-2-propenamide; N-(2-(2-(dimethylamino)ethyl-methylamino)-4-methoxy-5-((4-(1-methylindol-3-yl)pyrimidin-2-yl)amino)phenyl)prop-2-enamide; RefChem:58257; L01XE35; DTXCID401510212; Osimertinib [USAN]; N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide; MFCD27988062; C28H33N7O2; AZD 9291(Osimertinib); UNII-3C06JJ0Z2O; Mereletinib [INN]; Osimertinib (AZD9291); 2-Propenamide, N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-; N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide; AZD 9291; Osimertinib; Tagrisso; N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)acrylamide; Osimertinib (Standard); OSIMERTINIB [MI]; OSIMERTINIB [INN]; AZD9291 (Osimertinib); Osimertinib; AZD 9291; Osimertinib; AZD-9291; mereletinib (obsolete INN); AZD-9291(Osimertinib)?; OSIMERTINIB [WHO-DD]; GTPL7719; orb1226317; orb1305406; orb3141352; CHEMBL3353410; SCHEMBL14660911; SCHEMBL29350904; SCHEMBL29378405; EX-A314; MereletinibAZD-9291,Osimertinib; DUYJMQONPNNFPI-UHFFFAOYSA-N; GLXC-05459; HMS3653E10; HMS3672M05; HMS5085F14; MSK11040; NQC28144; TVB02091; BDBM50029668; EBC-07876; HY-15772R; NSC779217; NSC781254; NSC800812; s7297; AKOS025290756; CCG-264683; CS-2018; DB09330; FD58317; NSC-779217; NSC-781254; NSC-800812; SB22952; NCGC00378622-03; NCGC00378622-04; NCGC00378622-10; NCGC00378622-14; AC-29019; AS-16943; BP-43647; HY-15772; N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4- (1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide; 4714B; NS00073136; SW219863-1; T2490; EN300-7382438; A985134; BRD-K42805893-001-04-9; Q21506464; N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide; N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide; N-(2-{2-Dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide; N-[2-[2-(dimethylamino)ethyl-methyl-amino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamideSynonyme